553 related articles for article (PubMed ID: 24076267)
1. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.
Stingl JC; Bartels H; Viviani R; Lehmann ML; Brockmöller J
Pharmacol Ther; 2014 Jan; 141(1):92-116. PubMed ID: 24076267
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.
Ando Y; Ueoka H; Sugiyama T; Ichiki M; Shimokata K; Hasegawa Y
Ther Drug Monit; 2002 Feb; 24(1):111-6. PubMed ID: 11805731
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
[TBL] [Abstract][Full Text] [Related]
4. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs.
Villeneuve L; Girard H; Fortier LC; Gagné JF; Guillemette C
J Pharmacol Exp Ther; 2003 Oct; 307(1):117-28. PubMed ID: 12944498
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Bosch TM; Meijerman I; Beijnen JH; Schellens JH
Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
Bosch TM
Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
[TBL] [Abstract][Full Text] [Related]
7. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
Deguchi T; Watanabe N; Kurihara A; Igeta K; Ikenaga H; Fusegawa K; Suzuki N; Murata S; Hirouchi M; Furuta Y; Iwasaki M; Okazaki O; Izumi T
Drug Metab Dispos; 2011 May; 39(5):820-9. PubMed ID: 21282406
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors.
Johnson LA; Oetting WS; Basu S; Prausa S; Matas A; Jacobson PA
Eur J Clin Pharmacol; 2008 Nov; 64(11):1047-56. PubMed ID: 18568343
[TBL] [Abstract][Full Text] [Related]
9. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
Paoluzzi L; Singh AS; Price DK; Danesi R; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
J Clin Pharmacol; 2004 Aug; 44(8):854-60. PubMed ID: 15286088
[TBL] [Abstract][Full Text] [Related]
10. Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms.
Argikar UA; Iwuchukwu OF; Nagar S
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):879-94. PubMed ID: 18624677
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance.
Mackenzie PI; Miners JO; McKinnon RA
Clin Chem Lab Med; 2000 Sep; 38(9):889-92. PubMed ID: 11097345
[TBL] [Abstract][Full Text] [Related]
12. Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors.
Kasteel EEJ; Darney K; Kramer NI; Dorne JLCM; Lautz LS
Arch Toxicol; 2020 Aug; 94(8):2637-2661. PubMed ID: 32415340
[TBL] [Abstract][Full Text] [Related]
13. Study on the Optimal Dose of Irinotecan for Patients with Heterozygous Uridine Diphosphate-Glucuronosyltransferase 1A1 (UGT1A1).
Konaka K; Sakurada T; Saito T; Mori S; Imanishi M; Kakiuchi S; Fushitani S; Ishizawa K
Biol Pharm Bull; 2019; 42(11):1839-1845. PubMed ID: 31685767
[TBL] [Abstract][Full Text] [Related]
14. The effects of UDP-sugars, UDP and Mg
Walia G; Smith AD; Riches Z; Collier AC; Coughtrie MWH
Xenobiotica; 2018 Sep; 48(9):882-890. PubMed ID: 28868965
[TBL] [Abstract][Full Text] [Related]
15. UGT genotyping in belinostat dosing.
Goey AK; Figg WD
Pharmacol Res; 2016 Mar; 105():22-7. PubMed ID: 26773202
[TBL] [Abstract][Full Text] [Related]
16. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations.
Lampe JW; Bigler J; Horner NK; Potter JD
Pharmacogenetics; 1999 Jun; 9(3):341-9. PubMed ID: 10471066
[TBL] [Abstract][Full Text] [Related]
17. Warfarin is an effective modifier of multiple UDP-glucuronosyltransferase enzymes: evaluation of its potential to alter the pharmacokinetics of zidovudine.
Sun H; Zhang T; Wu Z; Wu B
J Pharm Sci; 2015 Jan; 104(1):244-56. PubMed ID: 25393417
[TBL] [Abstract][Full Text] [Related]
18. A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation.
Cai H; Nguyen N; Peterkin V; Yang YS; Hotz K; La Placa DB; Chen S; Tukey RH; Stevens JC
Drug Metab Dispos; 2010 May; 38(5):879-86. PubMed ID: 20124398
[TBL] [Abstract][Full Text] [Related]
19. UDP-glucuronosyltransferases and clinical drug-drug interactions.
Kiang TK; Ensom MH; Chang TK
Pharmacol Ther; 2005 Apr; 106(1):97-132. PubMed ID: 15781124
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene.
Lankisch TO; Vogel A; Eilermann S; Fiebeler A; Krone B; Barut A; Manns MP; Strassburg CP
Mol Pharmacol; 2005 May; 67(5):1732-9. PubMed ID: 15716465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
